Trials / Completed
CompletedNCT00499850
Phase I FOLFOX Combination
A Phase I,Open Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as First and Second Line Therapy in Patients With Advanced Colorectal Adenocarcinoma.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I,open label study to assess the safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD6474 (vandetanib) | once daily oral dose |
| DRUG | 5-Fluorouracil | intravenous infusion |
| DRUG | Leucovorin | intravenous infusion |
| DRUG | Oxaliplatin | intravenous infusion |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2006-06-01
- Completion
- 2008-04-01
- First posted
- 2007-07-12
- Last updated
- 2016-08-25
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00499850. Inclusion in this directory is not an endorsement.